EP
TRVI icon

Essential Partners’s Trevi Therapeutics TRVI Stock Holding History

Essential Partners’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$205 Hold
11
– – ﹤0.01% 2633
2026
Q1 		$131 Hold
11
– – ﹤0.01% 2681
2025
Q4 		$138 Hold
11
– – ﹤0.01% 2505
2025
Q3 		$101 Buy
+11
New +$82 ﹤0.01% 2491

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Essential Partners's TRVI Position: Q2 2026 in Review

Essential Partners held its Trevi Therapeutics (TRVI) position steady in Q2 2026 at 11 shares worth $205. The position accounts for ﹤0.01% of the portfolio, ranked #2633.

Essential Partners first reported a position in TRVI in Q3 2025 and has held it in 4 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Essential Partners held 11 shares of Trevi Therapeutics worth $205 as of Q2 2026.
  • Essential Partners left its Trevi Therapeutics share count unchanged in Q2 2026.
  • Trevi Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2633 holding.
  • Essential Partners first reported a position in Trevi Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.